[go: up one dir, main page]

GB201710812D0 - Method - Google Patents

Method

Info

Publication number
GB201710812D0
GB201710812D0 GBGB1710812.7A GB201710812A GB201710812D0 GB 201710812 D0 GB201710812 D0 GB 201710812D0 GB 201710812 A GB201710812 A GB 201710812A GB 201710812 D0 GB201710812 D0 GB 201710812D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1710812.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Francis Crick Inst Ltd
Francis Crick Institute Ltd
Original Assignee
Francis Crick Inst Ltd
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis Crick Inst Ltd, Francis Crick Institute Ltd filed Critical Francis Crick Inst Ltd
Priority to GBGB1710812.7A priority Critical patent/GB201710812D0/en
Publication of GB201710812D0 publication Critical patent/GB201710812D0/en
Priority to PCT/GB2018/051893 priority patent/WO2019008365A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1710812.7A 2017-07-05 2017-07-05 Method Ceased GB201710812D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1710812.7A GB201710812D0 (en) 2017-07-05 2017-07-05 Method
PCT/GB2018/051893 WO2019008365A1 (fr) 2017-07-05 2018-07-04 Méthode de traitement du cancer par un néo-antigène indel de déphasage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1710812.7A GB201710812D0 (en) 2017-07-05 2017-07-05 Method

Publications (1)

Publication Number Publication Date
GB201710812D0 true GB201710812D0 (en) 2017-08-16

Family

ID=59592566

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1710812.7A Ceased GB201710812D0 (en) 2017-07-05 2017-07-05 Method

Country Status (2)

Country Link
GB (1) GB201710812D0 (fr)
WO (1) WO2019008365A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827261A1 (fr) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Procédé de préparation de compositions immunogènes spécifiques à un sujet en s'appuyant sur une base de données de néo-peptides à cadre ouvert de lecture
CN111755067A (zh) * 2019-03-28 2020-10-09 格源致善(上海)生物科技有限公司 一种肿瘤新生抗原的筛选方法
IT201900016718A1 (it) * 2019-09-19 2021-03-19 Takis S R L Combinazione di agenti immunomodulatori con neoantigeni tumore-specifici per l’uso nella prevenzione e nel trattamento dei tumori.
EP4110956A1 (fr) * 2020-02-28 2023-01-04 CureVac Netherlands B.V. Néo-antigènes à cadre caché
CN115747327A (zh) * 2022-04-15 2023-03-07 成都朗谷生物科技股份有限公司 涉及移码突变的新抗原预测方法
EP4665387A2 (fr) * 2023-02-17 2025-12-24 Calviri, Inc. Peptides néo-antigènes de tryptophane pour diagnostics, agents thérapeutiques et vaccins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410922D0 (en) * 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
WO2003087162A2 (fr) * 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides et procedes utilises dans la detection et le traitement du cancer
US9732131B2 (en) * 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer

Also Published As

Publication number Publication date
WO2019008365A1 (fr) 2019-01-10

Similar Documents

Publication Publication Date Title
GB201701109D0 (en) Method
GB201706778D0 (en) Method
GB201704847D0 (en) Callibration method
GB201710815D0 (en) Method
GB201709333D0 (en) Method
GB201706544D0 (en) Method
GB201710812D0 (en) Method
GB201700352D0 (en) Method
GB201708853D0 (en) Method
GB201714645D0 (en) Method
GB201711066D0 (en) Method
GB201707140D0 (en) Method
GB201705897D0 (en) Method
GB201702250D0 (en) Method
GB201718631D0 (en) Method
GB201709387D0 (en) Method
GB201706079D0 (en) Method
GB201703898D0 (en) Method
GB2559410B (en) Method
GB201705444D0 (en) Method
GB201704536D0 (en) Method
GB201702096D0 (en) Method
GB201715251D0 (en) Method
GB201714417D0 (en) Method
GB201713597D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)